Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24799408 | 0.87 | MTNR1A (0.49) | CCR5ABCB1STAT3MRGPRX4MTNR1A | |
| Hydrochloric Acid SCHEMBL6215773 | 0.86 | CCR5 (0.75) | CCR5MAOBSTAT3MRGPRX4 | |
| Hydrochloric Acid SCHEMBL6214699 | 0.84 | CCR5 (0.63) | CCR5MAOBSTAT3MRGPRX4 | |
| Hydrochloric Acid SCHEMBL6213698 | 0.84 | MAOB (0.59) | CCR5MAOBABCB1MRGPRX4MTNR1A | |
| Hydrochloric Acid SCHEMBL6214570 | 0.83 | IDO1 (0.56) | CCR5ABCB1 | |
| SCHEMBL1196687 | 0.82 | CCR5 (0.64) | CCR5STAT3MRGPRX4 | |
| SCHEMBL22687788 | 0.81 | HSD17B10 (0.56) | ABCB1MRGPRX4NPC1RAB9AMTNR1A | |
| SCHEMBL20613050 | 0.81 | MEN1 (0.58) | CCR5ABCB1STAT3NPC1MTNR1A | |
| Hydrochloric Acid SCHEMBL6214742 | 0.81 | CCR5 (0.62) | CCR5STAT3MRGPRX4 | |
| SCHEMBL21218582 | 0.80 | MTNR1A (0.52) | STAT3MRGPRX4NPC1RAB9AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | CCR5 2406/4885MAOB 778/4885ABCB1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.